look at the report, the profit lower mainly due to inventories and research and development cost written off, professional fee, unrealised foreign exchange loss. But, the year to date result, the group posted a profit before tax of RM 4.01 million compared to a loss before tax of RM0.46 million a year ago. So basically still can be conclude that their business still running on right track. Next quarter result shall able to see better improvement.
Revenue increase significantly since 1Q17 when the company decided to venture into the trading of palm oil products which has since deliver higher revenue compared to the company’s original business of selling animal health products. This has helped increase the company profit to shareholder to RM3.5mil in FY17 from a loss of RM100k in FY16.
Then in mid FY17, management had proposed to diversify the company into the business of Chinese medicine via the acquisition of 70% of Ecolite Biotech for RM12.1mil. This acquisition was supposed to help increase the profit of the group by around RM1.8mil annually. The acquisition was completed in May 2018. However, based on the 3Q18 result, it does not seem that the acquisition had delivered on the expected profit expected by the shareholders. The newly acquired business posted a loss of RM500k in 3Q18.
Please take note, that the core losses in 3Q18 is actually around -RM5mil (after stripping out the gain from negative goodwill of RM3.6mil) and not the reported -RM1.4mil. All of the company’ s divisions fail to report any profit for the quarter.
Given the compression of profit margins seen in 3Q18 for all of the company’s main division (animal health products, palm oil trading and Chinese medicine), investors have to be prepared to see further losses in 4Q18 and potentially in the most part of FY19 as well.
If you are looking to diversify your portfolio outside of Sunzen (due to its weak earnings outlook), I would recommend you to look at MBMR.
MBMR is a direct proxy to Perodua via its 22.6% interest in the company. Valuation is cheap at only 6.9x PE (based on target FY18 profit of RM145mil. 9m profit is already RM106mil). PB is low at only 0.7x BV. 4Q18 results is expected to be higher than 3Q18 and last year's 4Q17.
FY19 growth will be driven by the still high demand of the new Myvi and the newly launched SUV Aruz and also the newly revamp Alza in 2H19. The recent announcement of closure and potential disposal of the loss-making alloy wheel manufacturing business alone is expected to boost the company’s profit by an additional RM20mil. I am projecting a profit to shareholder of RM170 mil for FY19 which at the current price values MBMR at only 5.9x PE.
Please go through the analyst reports (https://klse.i3investor.com/servlets/stk/pt/5983.jsp) and do your own analysis before making any decisions. There are 8 analysts in total covering the stock with most of them having a TP of above RM3 (all have a buy rating). The average TP for the 8 analysts is around RM3.50.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
hawhaw
177 posts
Posted by hawhaw > 2018-01-08 11:56 | Report Abuse
what happen?suddenly up so much